There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Shattuck Labs (STTK – Research Report) and Acrivon Therapeutics, Inc. (ACRV – Research Report) with bullish sentiments.
Acrivon Therapeutics, Inc. (ACRV)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc., with a price target of $22.00. The company’s shares closed last Tuesday at $8.69.
According to TipRanks.com, Bodnar is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acrivon Therapeutics, Inc. with a $23.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STTK:
- Shattuck Labs reports Q1 EPS (37c), consensus (45c)
- Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
